Form 4: Verona Pharma CEO David Zaccardelli Sells Shares Under 10b5-1 Plan

Verona Pharma's CEO, David Zaccardelli, executed sales of ordinary shares between October 18 and October 22, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• David Zaccardelli, the President and CEO of Verona Pharma plc, sold ordinary shares of the company between October 18 and October 22, 2024.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 8, 2024.
• On October 18, 2024, 245,784 ordinary shares were sold at a weighted average price of $4.3809 per share, resulting in a holding of 15,004,920 shares.
• On October 21, 2024, 110,456 ordinary shares were sold at a weighted average price of $4.3796 per share, resulting in a holding of 14,894,464 shares.
• On October 22, 2024, 157,912 ordinary shares were sold at a weighted average price of $4.3868 per share, resulting in a holding of 14,736,552 shares.
• The reported securities are represented by American Depositary Shares (ADSs), with each ADS representing eight ordinary shares.
• The sales prices ranged from $4.3750 to $4.4063 per ordinary share (or $35.00 to $35.25 per ADS) on October 18, $4.3750 to $4.3913 per ordinary share (or $35.00 to $35.13 per ADS) on October 21, and $4.375 to $4.4438 per ordinary share (or $35.00 to $35.55 per ADS) on October 22.
• Following these transactions, Zaccardelli directly owns 14,736,552 ordinary shares, including shares underlying Restricted Share Units and ADSs.

Sentiment

Score: 5

Explanation: Neutral sentiment as the filing simply reports transactions under a pre-existing trading plan. It doesn't inherently indicate positive or negative views on the company's future prospects.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders and are closely watched by investors for insights into management's perspective on the company's stock. Sales under 10b5-1 plans are generally less concerning as they are pre-arranged.

Stakeholder Impact

• The share sales by the CEO may have a minor impact on shareholder sentiment, although the existence of a pre-arranged trading plan mitigates potential concerns.

Key Dates